Anti-vascular endothelial growth factor therapy in breast cancer: game over?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Clinical Oncology

• Publication date

  2015-01-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2014.58.1298PMID 25349299
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

  2015cited by this paper
• Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy

  2014cited by this paper
• a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

  2014cited by this paper
• Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.

  2014cited by this paper
• Control of the Immune Response by Pro-Angiogenic Factors

  2014cited by this paper
• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)

  2014cited by this paper
• First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

  2013cited by this paper
• Predictive Biomarkers for Bevacizumab: Are We There Yet?

  2013cited by this paper
• Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

  2013cited by this paper
• Mechanisms of resistance to anti-angiogenesis therapies.

  2013cited by this paper
• Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.

  2013cited by this paper
• Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.

  2013cited by this paper
• Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

  2013cited by this paper
• First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

  2012cited by this paper
• Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?

  2011cited by this paper
• Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

  2011cited by this paper
• A novel function for programmed death ligand-1 regulation of angiogenesis.

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

  2010cited by this paper
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• VEGF-Targeting Therapy for Breast Cancer

  2005cited by this paper
• Angiogenesis and antiangiogenic therapy.

  2002cited by this paper
• The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

  2001cited by this paper
• Paclitaxel (Taxol): An Inhibitor of Angiogenesis in a Highly Vascularized Transgenic Breast Cancer

  1999cited by this paper
• A cancer therapy resistant to resistance

  1997cited by this paper

• Flow-Induced Vascular Remodeling On-Chip: Implications for Anti-VEGF Therapy

  2024cites this paper
• Molecular principles of tissue invasion and metastasis.

  2023cites this paper
• Extracellular Matrix-Derived Biophysical Cues Mediate Interstitial Flow-Induced Sprouting Angiogenesis.

  2023cites this paper
• [Agkistrodon halys venom antitumor component-I inhibits vasculogenic mimicry in triple-negative breast cancer cells in vitro by down-regulating MMP2].

  2022cites this paper
• Breast cancer.

  2022cites this paper
• Structural Determination of the Nanocomplex of Borate with Styrene-Maleic Acid Copolymer-Conjugated Glucosamine Used as a Multifunctional Anticancer Drug.

  2022cites this paper
• Pharmacoeconomic Evaluation of Bevacizumab in Combination with Paclitaxel in the First-line Treatment of Patients with HER-2 Negative Metastatic Breast Cancer

  2021cites this paper
• Heterogeneity and vascular permeability of breast cancer brain metastases.

  2020cites this paper
• Tumor Microenvironment

  2020cites this paper
• Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements

  2020cites this paper
• Pharmacogenomics, Pharmacokinetics and Circulating Proteins As Biomarkers for Bevacizumab Treatment Optimization in Patients with Cancer: A Review

  2020cites this paper
• MDA-9/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis.

  2020cites this paper
• Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation

  2019cites this paper
• Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment.

  2019cites this paper
• Pericytes in Breast Cancer.

  2019cites this paper
• Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer

  2019cites this paper
• Identification of protein targets and the mechanism of the cytotoxic action of Ipomoea turpethum extract loaded nanoparticles against breast cancer cells.

  2019cites this paper
• An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?

  2019cites this paper
• Bevacizumab Moonshots: An Important Outcome From the Latest Ovarian Cancer Mission.

  2019cites this paper
• Notch1 in Tumor Microvascular Endothelial Cells and Tumoral miR-34a as Prognostic Markers in Locally Advanced Triple-Negative Breast Cancer

  2019cites this paper
• A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway.

  2018cites this paper
• Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment

  2018cites this paper
• Next generation sequencing‐based gene panel tests for the management of solid tumors

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1512 Neuropilin-1 regulation of tumor vascularization and growth

  2018cites this paper
• Angiogenic role of miR-20a in breast cancer

  2018cites this paper
• Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs

  2018cites this paper
• HPMA copolymer conjugate with pirarubicin: In vitro and ex vivo stability and drug release study.

  2018cites this paper
• N‐(2‐hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide‐a, a promising tumor‐targeted theranostic probe for photodynamic therapy and imaging

  2018cites this paper
• Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

  2018cites this paper
• The soluble nectin-4 ecto-domain promotes breast cancer induced angiogenesis via endothelial Integrin-β4.

  2018cites this paper
• Validation of biomarkers and digital image analysis in breast pathology

  2017cites this paper
• Advancing Immunotherapy in Metastatic Breast Cancer

  2017cites this paper
• Oncostatin M Promotes Breast Cancer Metastasis: Increased Expression of Pro-Angiogenic Factors, Inflammatory Cytokine Expression, and Circulating Tumor Cell Numbers

  2017cites this paper
• Introduction to Interrelated Biology of Age-Associated Chronic Diseases and Cancer: Chronic Inflammation, a Common Denominator in Morbidity and Mortality

  2017cites this paper
• Targeting metastasis

  2016cites this paper
• Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity.

  2016cites this paper
• Emerging therapeutic targets in metastatic progression: A focus on breast cancer.

  2016cites this paper
• Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment.

  2016cites this paper
• HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies

  2016cites this paper
• VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer

  2016cites this paper
• Safety concerns and hidden agenda behind HPV vaccines: another generation of drug-dependent society?

  2016cites this paper
• Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer

  2015cites this paper
• Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis

  2015cites this paper
• Targeted therapy in gastroesophageal cancers: past, present and future

  2015cites this paper
• Angiogenesis Inhibitors in the Treatment of Breast Cancer: Exploring Avenues of New Therapeutic Targets

  2015influential citation
• Effects of Mfn2 Gene Overexpression on EGFR Expression and Angiogenesis of a Heterologous Graft Model for Human Breast Infiltrating Duct Carcinoma in Nude Mice

  2015cites this paper
• Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.

  2015cites this paper
• Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients

  2015influential citation
• Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

  2014cites this paper